$15.5m · Series B · Healthtech · Stockholm, Sweden
Pixelgen Technologies has closed an oversubscribed $15.5m Series B led by new investor Flat Capital, with existing investors Industrifonden and Navigare Ventures also participating. According to the company announcement, the Stockholm-based life-sciences company will use the financing to accelerate global commercialisation of its Proxiome Kit, expand in key markets, grow its team and product portfolio, and scale its data-analysis and visualisation software.
Flat Capital said it invested about SEK 40m in the approximately SEK 150m round. Its investor announcement describes Pixelgen's customers as leading academic institutions and pharmaceutical companies, primarily in Europe and North America.
Turning molecular maps into a laboratory workflow
Most proteomics tools measure how much of a protein is present. Pixelgen's Proxiome Kit is designed to show how proteins are organised, clustered and localised on the surface of individual cells. That distinction matters because the spatial arrangement of cell-surface proteins helps govern signalling, communication and treatment response. The underlying Molecular Pixelation method uses DNA-tagged antibodies and sequencing to reconstruct spatial protein networks without fluorescence microscopy.
A peer-reviewed Nature Methods paper described the method as an optics-free approach that arranged sequencing reads into spatial networks for 76 proteins across individual cells. In the study, the researchers detected changes in protein organisation associated with immune-cell stimulation and therapeutic-antibody treatment. The paper also noted a limitation: the polymer structure of the DNA pixels makes precise spatial-resolution assignment difficult.
Commercially, Pixelgen is trying to turn that research method into a repeatable platform for laboratories. The kit and its analysis software must fit existing experimental workflows closely enough for researchers to compare disease states, treatment responses and patient cohorts, while producing data that can be interpreted consistently. The financing therefore supports more than geographic sales expansion: it funds the product, software and application work needed to make a specialist assay usable across more research programmes.
Commercialisation experience joins the board
The round also brings Flat Capital CEO Rickard El Tarzi and life-sciences software entrepreneur Ramon Felciano onto Pixelgen's board. The company says Felciano will help build the digital capabilities around its molecular-cell-architecture platform, while El Tarzi brings experience from Olink Proteomics' expansion, IPO and eventual sale to Thermo Fisher Scientific.
That board composition reflects the next execution challenge. Pixelgen has already published the underlying method and commercialised a kit; it now has to convert technical differentiation into broader adoption by academic and pharmaceutical laboratories. Scaling the installed workflow, software layer and market support together is what can turn a novel assay into a durable research platform.
